Senseonics Holdings has partnered with diabetes management companies Roche Diabetes Care and TypeZero Technologies to develop a long-term automated insulin delivery system.  

The new system will be used in the international diabetes closed loop (IDCL) clinical trial, which is being funded by the US National Institutes of Health (NIH) to evaluate automated insulin delivery devices.

IDCL is designed to integrate Senseonics’ long-term, implantable continuous glucose monitoring (CGM) system Eversense with Roche’s Accu-Chek Insight Insulin Pump, and TypeZero’s inControl AP algorithms.

Eversense features a small, fluorescence sensing technology-based CGM sensor that lasts for approximately 90 days.

"The promise of automated insulin delivery systems is the ability to automatically and sustainably maintain tight glucose control while avoiding hypoglycaemia."

Upon subcutaneous insertion, the sensor continually measures glucose levels and wirelessly transmits them to a mobile application via a smart transmitter. 

inControl software has been developed to use the combination of data obtained from the CGM system and the pump for automatic adjustment and regulation of insulin delivery. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Senseonics president and CEO Tim Goodnow said: "The promise of automated insulin delivery systems is the ability to automatically and sustainably maintain tight glucose control while avoiding hypoglycaemia. 

"With this partnership, we are one step closer to bringing this promise to market and to significantly improve the everyday challenges of people with diabetes."

Aimed at reducing the burden of disease for diabetic patients, the IDCL trial will be conducted at the University of Amsterdam in the Netherlands, Italy's University of Padova, and France's University Hospital of Montpellier.